Shares of Sarepta Therapeutics (Nasdaq:SRPT) were gapping down Tuesday morning with an open price 11.7% lower than Monday's closing price. The stock closed at $39.24 yesterday and opened today's trading at $34.65.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Shares of Sarepta Therapeutics (Nasdaq: SRPT) were gapping down Tuesday morning with an open price 11.7% lower than Monday's closing price. The stock closed at $39.24 Monday and opened today's trading at $34.65.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The average volume for Sarepta has been 1.6 million shares per day over the past 30 days. Sarepta has a market cap of $1.28 billion and is part of the health care sector and drugs industry. Shares are up 55.9% year to date as of the close of trading on Monday. Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. TheStreet Ratings rates Sarepta as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. You can view the full Sarepta Ratings Report. Get more investment ideas from our investment research center. It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.